Kynurenine-3-monooxygenase (KMO) inhibition as a novel therapeutic strategy to enhance islet cell viability and improve outcomes of Islet Cell Transplantation

Project Details

StatusActive
Effective start/end date1/12/2130/11/24

Funding

  • MRC: £340,706.00